Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from TuHURA Biosciences ( (HURA) ) is now available.
On June 2, 2025, TuHURA Biosciences entered into a securities purchase agreement with investors to issue 4.76 million shares of common stock and warrants in a private placement, raising approximately $12.6 million. By September 5, 2025, the company and deferral investors agreed to purchase $3.2 million of the remaining offering amount, with the company extending the expiration dates of certain warrants to December 31, 2030, impacting the company’s financial strategy and investor relations.
The most recent analyst rating on (HURA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.
TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative therapies. The company engages in securities offerings to fund its operations and expand its market presence.
Average Trading Volume: 489,622
Technical Sentiment Signal: Sell
Current Market Cap: $118.6M
Find detailed analytics on HURA stock on TipRanks’ Stock Analysis page.